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Siary We ingated the pattern and frequency of ovarian metastases in patients with primary gastro-
intestinal malgnancies and evaluated the response to surgery, chemoterapy and three ca radiothrapy.
The lterature reports that ths group of patients have a poor prognosis, but no report has
addressed the response to chemotherapy. Using a database which is generated poetl, we analyse 51
patients with primary astrointestinal malignances and ovarian netastases. All paiets recived
chemotherapy but only 36 were evaluable for response; five had adjuvant treatment and ten had non-
measurable diseas. Seventeen patients had surgical oophorectomy and three patients received radiotherapy.
Tlhe overall response rate to chemotherapy was 22%; eight partial Lesponses and no complete rsonses. When
straified ing to site of response, 11 (31%) patients had a partial response at sites of extraovarian
metastases and only five (14%) had a partial response in the ovaries. Seven patients with primary colorectal
cancer had a differential response in favour of extaovarian sites. The median survival was 9 months for the 51
patients. Thee premenopausal women with reseted gastric ived adjuvant chemotherapy and
relapsed only in the ovaries. In primary colorectal tumours the response of ovarian measases to
chemotherapy is less than that for other sites. Tberefore, the ovary may be a sanctuary site for metastase
which has important impations for adjuvant chemotherapy in women. These women could be followed up
regularly by transvaginal utrasonography to detect such meastases at an early stage when they would be
amenable to surgical resetion. Surgery should be idered for sected patients who develop metachronous
metastases, as patients may be rendered diseas free for several months.
Keyword= ovarian meastases; colorectal adjuvant chemotherapy
The ovary is a relatively frequent site of metastases from
malignant neoplasms arising anywhere in the body. Ovarian
metastases constitute 76% of genital tract metastases from
extragenital primary tumours, of which 78% arise in the
gastrointestinal tract (Mazur et al., 1984). Secondary
tumours of the ovary constitute 10% of all ovarian neo-
plasms (Blaustein, 1982). In premenopausal women with col-
orectal cancer the incidence of ovarian metastases either
found at the time of initial surgery or developing subse-
quently is reported to be between 13.2% and 25% (Recalde
et al., 1974; Walton et al., 1976; MacKeigan and Ferguson,
1979). Similar rates have been reported for stomach cancer
(Warren and Macomber, 1935; Webb et al., 1975). The term
'Krukenberg tumour' has become dinically synonymous with
the pnce of any metastasis to the ovaries, although
purists contend that true Krukenberg tumours should meet
the criteria established by Novak and Gray in 1938 and
currently used by the WHO (Serov and Scully, 1973):
(1) presence of cancer in the ovary;
(2) intracellular mucin production by neoplastic signet-ring
cells; and
(3) diffuse sarcomatoid proliferation of the ovarian stroma
When lesions of this particular histology are analysed in
terms of the primary neoplasn, gastric carcinoma is the most
common source of ovarian metastases (Hale, 1968; Woodruff
and Novak, 1960). Other ovarian metastases are of non-
Krukenberg type and at times may be difficult to distinguish
from primary ovanan carcnoma. The frequent use of com-
puteised tomographic (CT) nning nowadays to assess and
follow up patients with tumours of the gastrointestinal tract
results in the discovery of otherwise unsuspected ovarian
metastases, the features of which are described in a separate
report (in preparation). Many of the patients in this report
did not have histological confirmation of malignancy in the
ovary because they had never undergone oophorectomy.
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However, the unequivocal change in ovarian size and
appearance over the course of a patient's illness was consis-
tent with malignant involvement.
This report reviews ovarian metastases from primary gas-
trointestinal mlimanci regardless of whether they were
classal Krukenberg tumours or non-Krukenberg tumours,
as in many instances it was not possible to differentiate
between the two. The pathologial features of cl
Krukenberg tumours are well described elsewhere (Wong et
al., 1986). assical Krukenberg tumours are reported to
occur in younger premenopausal women, occasionally occur-
ring during or shortly after pregnancy (Ward, 1966; Holz and
Hart, 1982), suggesting a hormonal effect as one of the
aetiological factors in its occurrence.
It has been postulated that the rearrangement of the
ovarian surface in the post-ovulatory period and increased
vascularity favour the seeding and growth of metastases
(Sternberg, 1963). The diagnosis of Krukenberg tumours has
been reported to be associated with a poor prognosis (Mason
and Kovalich, 1981), but the use ofaggressive chemotherapy
or surgery in these patients is not well described. Endo-
crinological symptoms related to ovarian dysfunction have
been reported (Raquiz, 1991; Scully and Richardson,
1961).
In this report we describe the clinical fings in patients
with ovarian metastases in association with a primary gastro-
intestinal malignancy. Metastases were documented either
surgically or by serial computerised tomography of the pel-
vis. All patients received chemotherapy at some stage of their
illness, and we have a the response to treatment. In
addition, some patients underwent resection of their ovarian
metastases, and three had pelvic radiotherapy. The potential
benefits of these two therapeutic modalities are dis ed.
M dteiak and
Patients
Using a database which is generated prospectively, we have
analysed all patients presenting to the Royal Marsden Hos-AE Ta et
AET;bor etatw
pital with primary gastrointestinal malignancies who at some
stage developed ovarian metastases (antechronous, syn-
chronous or metachronous). Patients of any age were in-
cluded if they had histological confirmation of a primary
tumour in the gastrointstinal tract (oesophagus, stomach,
pancreas, colon or rectum) as reviwed by a pathologist at
the Royal Marsden Hospital or ovarian metastases confirmed
at surgery or demonstrated on a series of CT pelvis scans
reviewed retrospectively by the same radiologist. Patients
were excluded ifthey had dual malignancies or a past history
of malignancies outside the gastroiestial tract (with the
exception of squamous or basal cell carcinoma ofthe skin or
in situ carcinoma of the cervix). Patients were included
regardless ofthe treatment received, but over this time period
all patients received chemotherapy. Patient characteristics are
shown in Table I.
Assessnent ofresponse
Patients were evaluated before treatment by clinical exaimna-
tion, chest radiography, CT abdomen/pehlis and blood tests
for biochemistry, haematology and CEA (carcinoembryonic
antigen). Patients were re-evaluated on subsequent occasions
according to the type of treatment they were reiving, Re-
sponse was defined according to WHO criteria as follows:
complete response (CR), the disappearance of all known
diseas as determined by two separate obsrvations separated
by no kss than 4 weeks; partial remission (PR), a >50%
decrease in the product of bidimensionally measured lesions
as determined by two obsrvations separated by no less than
4 weeks and the absence of new lesions; stable disease (SD),
a <50% decrease and a <25% increase in the product of
bidimensionally measured lesions; and progressive di
(PD), a >25% increase in the size of measurable lesions
and/or the appearance of new lesions.
Statistis
Binomial confidence intervals for the response rates were
alculated usig the method of tail probabilities.
Treatment
Seventeen patients underwent surgery for removal of their
ovarian metastases, and the time of surgery in relation to the
diagnosis of the priary tumour was: antechronous, two
cases; synchronous, four cases; metachronous, 11 cases
(Table II). Tlwhree patients with metachronous ovarian meta-
stases had received adjuvant chemotherapy for resected gas-
tric carcinoma and the ovary was the sole site of relapse. All
Tabl I Patient characteristics
Tumour type
Colorectal
Oesophagot
Pancreas
Small bowel
Unknown
Histology
Adenocarcinoma
Small cei
Carcinoid
Laterality
Bilateral
Unilateral
Age (years)
<40
>40
Surgery for ovarian tumour
Yes
No
Family history of cancer
25
19
2
2
3
41
39
12
9
42
17
34
0
paitents recived chemotherapy based on the practices of the
unit at that time for individual tumour types. Colorectal
cancer patients received schedules containing 5-fluorouracil.
Patients with oesophagogastric, pancreas or unknown
primary cancers received combination chemotherapy, usually
with cisplatin and 5-fluorouracil.
Res
Patient characteristics (Table H)
Fifty-one patients were found to have ovarian metastases out
ofa total of 828 patients with primary gastrointesinal malig-
nancies over the period September 1989 to May 1993, which
represents 6.2% of all cases and 16% of female cases. The
site of the primary tumour was: colorectal, 25 cases; oeso-
phagogastric, 19 cases; small bowel, two cases; pancreas, two
cases; and unknown primary three cases (two found to be
pancreas at autopsy). The histology of the primary tumour
was adenocarcinoma in 49 cases; small cell carcnoma in one
case and carcinoid tumour in one case. Patients were aged
from 33 to 76 years (median 49 years); 50% were less than 50
years, one patient was post-partum and one patient had been
receiving the ovulatory-stimulating hormone clomiphee.
Twenty-nine per cent of the database patients were female
less than 50 years, but this group constituted 50% of those
who developed ovarian mettases. Nime patients were less
than 40 years. Ovarian metastases were confirmed surgically
in 17 cases and by CT scan of the pehlis in the other 34
cases 39 were bilateral and 12 unilateral. The ovary was the
sole site of metastases in five cases. In the remaining cases
metasta were reported in the following sites: liver, 23
cases; lung, 16 cases; peritoneum 16 cases; lymph nodes, 20
cases, abdominal wall, two cass.
Response to treatment
The response to treatment was evaluated and stratified ac-
cording to primary tumour type. Of the 51 patients sse
in the study, 36 had measurable disease in the ovaries as well
as at extrovarian sites. The overall response was partial
response in eight patients (22%) and complete response in no
patients. However, a total of 11 patients had a partial re-
sponse at extraovarian sites, and only five of these had a
partial response in the ovaries. One patient had a differential
response characterised by response at an extraovarian site
while the ovarian disease emained stable, and six patients
responded at extraovarian sites but synchronously developed
new lesions in the ovaries while stfill responding (Table HI).
The duration ofresponse for responders was 2.5 months. The
median survival for the 51 patients was 9 months, and for the
patients who responded to chemotherapy was 20 months.
Interestingly, three women less than 50 years who received
adjuvant chemotherapy for gastric carcinoma relapsed solely
in the ovary, and after surgical resection all remain alive and
well 6, 10 and 28 months after surgery. Two women devel-
oped ovarian metastases while on adjuvant chemotherapy for
colorectal carcinoma: one had an oophorectomy but has
developed recurrent pelvc disease and the other has isolated
ovarian metaa awaiting surgery.
Response to radiotherapy
Only three patients had pelvic radiotherapy, two preceding
chemotherapy and one after unsuccessful chemotherapy; all
patients responded, two partially and one completely.
Response to surgery
The 17 patients who had surgery had a subsequent disease-
free period oN-28 + months following surgery (Table H).
Surgery was performed at widely differing times in the course
of the patient's disease.9 ~~~~~~~~~~~~~~~~~~~AE Taylor etal
94
Table II Surgery performed in patients with ovarian metastases
Time in relation to primar) Timne interval to
tumours Procedure recurrent disease
Antechronous
1 Bilateral salpingo-oophorectomy Primary discovered 4 months
later. Lost to follow-up
2 Bilateral salpingo-oophorectomy 15 months + alive and well,
receiving chemotherapy, no
evidence of disease
Synchronous
3 Gastrectomy/bilateral oophorectomy 6 months
4 R oophorectomy/small bowel resection 12 months +
5 (a) L hemicolectomy/R oophorectomy 15 months
(b) Resection rcurrent pevic disease 2 months
(c) Resection recurrent pelvic disease 2 months, alive with disease
6 Resection of jejunum and bilateral 3 months
salpingo-oophorectomy
Metachronous
7 (a) R oophorectomy 16 months
(b) L oophorectomy 8 months
8 Bilateral oophorectomy (6 years post 1 month
resection of primary tumour)
9 Bilateral oophorectomy (following 5 months
partial response to chemotherapy)
10 (a) L oophorectomy (after no response 2 months
to chemotherapy
(b) R oophorectomy (after no response I + months
to chemotherapy)
11 L Oophorectomy 6 months
12 Bilateral oophorectomy 8 months
13 Bilateral oophorectomy (4 years after 2 months
gastrectomy for primary stomach)
14 Bilateral oophorectomy (at time of 0
surgery for small bowel obstruction,
other disease present)
Following adjuvant
chemotherapy for resected
gastric carcinoma
15 Bilateral salpingo-oophorectomy No recurrence 6 months +
16 Bilateral salpingo-oophorectomy No recurrence 10 months +
17 Bilateral salpingo-oophorectomy No recurrent 28 months +
Table m Responses to chemotherapy stratified for primary site (evaluable patients only)
Responses at
extraovarian sites Responses in ovary Overall responses
Primary site Nwnber ofpatients CR PR SD PD CR PR SD PD CR PR SD PD
Colorectal 20 0 8 8 4 0 1 9 10 0 4 6 10
Oesophagogastric 10 0 1 7 2 0 2 7 1 0 2 6 2
Pancreas 2 0 0 2 0 0 0 2 0 0 0 2 0
Small bowel 1 0 0 1 0 0 0 1 0 0 0 1 0
Unknown 3 0 2 1 0 0 2 1 0 0 2 1 0
Total 36 0 11 19 6 0 5 20 11 0 8 16 12
(%) (0) (31) (53) (17) (0) (14) (55) (31) (0) (22) (44) (33)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. aPercntage to nearest figure.
DEsasso
Although there are many reports of ovarian metastases in the
literature, we believe this is the largest series which
specifically addresses the value of chemotherapy in these
patients. Ovarian metastases can occur from any primary site
within the gastrointestinal tract, although colorectal followed
by oesophagogastric metastases were the most frequent in
this series. As more active regimens are being evaluated in
metastatic colon and gastric carcinoma, it is imperative to
know if certain disease sites respond more favourably than
others so that patients who are unlikely to benefit are spared
unnecessary treatment. This series shows an overall response
rate of 22% to chemotherapy, which in the setting of meta-
static gastrointestinal malignancies is no lower than would be
expected for some of the individual tumour types with the
most current active regimens. These patients were all treated
in the last 4 years and received what was considered to be the
best available treatment for their tumour type. When re-
sponse was stratified according to site of metastases, the
overall response rate in the ovary was 14% (CI 0.047-0.295),
which is lower than the 31% extrovarian sites (CI
0.163-0.481). Ovarian metastases were surgically confirmed
in only 17 (33%) of the cases.
Another explanation for the differential responses seen in
at least some cases may be the true occurrence of a second
primary in the ovary. In these cases the ovarian tumour
would be unlikely to respond to 5-fluorouracil-based chemo-
therapy. However, as there was no reported family history of
multiple primary cancer syndromes or other cancers, this
explanation would be likely to account for only a small
number of the total cases. In addition, multiple primaries areAETaylor eti
more frequent in patients less than 40 years, and only 9 of
the 51 patients were in this group. It was neither ethical nor
practical to biopsy all the ovarian masses. Radiologically
they were presumed in the context ofa proven primary lesion
to be metastases. Supporting this presumption was the
absence of a significant amount of ascites, seen only in four
patients towards the end of treatment. Primary ovarian
cancer is frequently assocated with a larg amount ofascites.
In only 30% were large ovarian masses seen on the first CT
scan; the rzmainder developed while patients were on treat-
ment and were observed over a 6 month to 2 year period.
The differential response was especially evident when the
primary site was colorectal and suggests that ovarian meta-
stases from primary colorectal cancer are relatively resistant
to chemotherapy compared with non-ovarian metastases.
Therefore, the ovary may be a sanctuary site analogous to
the testis in other malignancies. Also suggestive of such
sanctuary sites is the three cases ofsolitary ovarian relapw in
patients who received adjuvant therapy, although no definite
conclusions can be drawn. In particular, patients with
primary colorectal cancer had a 40% response rate (CI
0.19-0.64) at extraovarian sites compared with a 5% (CI
0.001-0.25) response rate in the ovary, although the
confidence intervals overlap because of the small number of
patients (Table IV). Patients with metastatic gastrointestinal
tumours cannot be cured, but there is now evidence that
patients with hepatic metastases from colorectal carcinoma
have an improved survival with palliation of symptoms if
they receive chemotherapy (Poon et al., 1989; Nordic Gastro-
intestinal Tumour Adjuvant Therapy Group, 1993). If palli-
ation of symptoms at extrovarian sites can be achieved by
chemotherapy, then large ovarian metastases from a colorec-
tal primary may remain a significant source of morbidity, as
this series suggests that they respond minimally to chemo-
therapy. Pathological studies have demonstrated involvement
of the ovary in 3-8% of colorectal cancer patients (Abrams
et al., 1950; Wheelock and Putong, 1959). Prospective studies
in which prophylactic oophorectomy has been performed in
patients with colorectal cancer show the incidence of ovarian
involvement to be between 7.4% and 11.3% (MacKeigan and
Ferguson, 1979; Holtz and Hart, 1982). Microscopic disease
has been reported in 3% of patients (MacKeigan and Fer-
guson, 1979). Several authors have advocated prophylactic
oophorectomy for women with colorectal cancer (Burt, 1951;
Barr et al., 1962; Antonaides et al., 1977; MacKeigan and
Ferguson, 1979; Graffner et al., 1983) but this has not
become accepted standard practice. The argument against
prophylactic oophorectomy is the lack ofevidence showing a
survival benefit in any of the studies performed. A retrospec-
tive study from the Mayo Clinic (Ballantyne et al., 1985)
reviewed 571 women who underwent curative resection of
colon cancer. The overall 5 year survival was 78% for
Table IV 95% confidence intervals for response rates
Extraovarian Ovarian Overal
Colorectal 0.1910-0.639 0.001-0.249 0.057-0.437
Oesophagoastric 0.003-0.445 0.025-0.556 0.025-0.556
Pancreas 0.0-0.841 0.0-0.841 0.0-0.841
Smal bowel 0.0-0.975 0.0-0.9575 0.0-0.975
Unknown 0.094-0.991 0.094-0.991 0.095-0.091
oophorectomised women and 73% for others, a difference of
5%, but the sample size was not large enough to reach
staisical signifi. This survival difference is silar to
the reported frequency of ovarian metastases associated with
colon cancer. However, the real issue is not about increasing
overall survival as the ovary is unlikely to be the only site of
metastatic disease in the majority of patients with metastatic
gastrointestinal malignancies. What is more crucial is that,
should ovarian metastases occur, then they are potentially
the source of significant morbidity and, unlike disease at
other metastatic sites, this report demonstrates that they are
less responsive to chemotherapy. This study shows that
premenopausal women have a proportionally higher inci-
dence of ovarian metastases. As adjuvant chemotherapy has
been shown to be worthwhile in colorectal cancer, a potential
sanctuary site for microscopic tumour is of concern. Pro-
phylactic oophorectomy with its attendant complications and
lack of survival benefit cannot be justified in these women.
However, it would be a relatively simple matter to follow
such women by regular transvaginal ultrasonography, especi-
ally in the premenopausal group. Early surgical resection of
ovarian metastases may avoid the situation where extra-
ovarian metastases respond to chemotherapy but the patient
continues to have an enlarging symptomatic pelvic mass
resistant to chemotherapy.
For patients who develop ovarian metastases subsequent
to their primary surgery, a second operation is not often
contemplated because of the presence of concurrent disease
at other sites or because of unfitness for surgery. The small
number of patients in this report who had surgery had
several months disease free, which must be considered worth-
while palliation, even though they subsequently died of
disease at other sites. Patients with widespread metastases
who achieve a good response to chemotherapy at extra-
ovarian sites but have unresponsive ovarian metastases caus-
ing symptoms or with impending symptoms should be con-
sidered potential candidates for palliative surgical resection
or palliative radiotherapy as the few patients treated with
radiotherapy all responded.
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